State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
Auto-generated profile, based on publicly available information
Shuo Yang
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
Hs-cTnT concentrations are age and gender related, therefore establishment of age and gender optimized cutoff values for hs-cTnT might be essential. We aimed to define the age and gender specific hs-cTnT 99th percentile in reference population and assess its diagnostic and prognostic performance in patients with suspected AMI. In this prospective study, 1725 healthy individuals (18 - 97 years old) and 812 patients (15 - 98 years old) with chest pain with suspected AMI presenting to the emergency department were enrolled. The measurement of biomarkers was performed at presentation and at 3 - 4 hours according to clinical requirement. We stratified the reference population by age and gender through applying strict exclusion criteria. Clinical follow-up was obtained after 2 years. The 99th percentile of hs-cTnT according to age and gender in adult Han population of Northern China is reported. The cutoff values of hs-cTnT in for subjects < 70 years, 70 - 79 years, and ≥ 80 years was 16 ng/L, 38 ng/L, and 57 ng/L, respectively. Among the 812 patients with chest pain, according to the age and gender tailored cutoff value, the specificity and positive predictive value of AMI diagnosis were increased from 53.9% to 72.2% and 48.6% to 60.8%, compared to 14 ng/L commonly recommended. Cumulative 2-year survival rate for patients with hs-cTnT levels above 14 ng/L was 93.3% compared to 99.5% in patients below that level (p < 0.001). The same was observed for the age and gender tailored cutoff value which was 92.5% compared to 98.5%, respectively (p < 0.001). Age and gender tailored cutoff value for hs-cTnT provides better diagnostic information, but yields no additional prognostic performance for risk prediction of death or major adverse cardiovascular events.
Introduction Endometrial thickness is an important parameter to evaluate endometrial receptivity. An appropriate endometrial thickness is necessary for both embryo implantation and maintaining normal pregnancy. Women with thin endometrium are one of the critical challenges in the clinic, and current therapeutic strategies for thin endometrium remain suboptimal. The stromal vascular fraction (SVF) derived from adipose tissue contains a variety of cells, mainly adipose-derived stem/stromal cells and adipose cells. Recently, adipose tissue-derived SVF showed tremendous potential for treating thin endometrium due to its capacity to repair and regenerate tissues. The application of SVF in animal models for treating thin endometrium has been investigated. However, limited evidence has demonstrated the efficacy and safety of autologous SVF in patients with thin endometrium. Methods and analysis This study is a single-centre, longitudinal, prospective self-control study to investigate the preliminary efficacy and safety of autologous SVF in improving the pregnancy outcome of infertile patients with thin endometrium. Thirty patients diagnosed with thin endometrium will be recruited based on the inclusion and exclusion criteria. The SVF suspension will be transferred into the uterine cavity via an embryo transfer catheter. Then, comparisons between pretreatment and post-treatment will be analysed, and the outcomes, including endometrial thickness, menstrual volume and duration, frequency and severity of adverse events and early pregnancy outcomes, will be measured within a 3-month follow-up, while late pregnancy outcomes and their offspring will be followed up via telephone for 2 years. The proportion of patients with improved symptoms will be calculated and compared. Ethics and dissemination This study was approved by the Ethics Committee of Peking University Third Hospital (reference number: REC2020-165). Written informed consent will be provided for patients before being included. The results will be presented at academic conferences and a peer-reviewed journal. Trial registration number ChiCTR2000035126.
21 January 2022 in Archives of Gynecology and Obstetrics